Improving prevention and treatment of venous thromboembolism: clinical trial results

References

• US Department of Health and Human Services. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. 2008. http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf. Accessed February 6, 2012
   Google Scholar
• Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
   PubMed Web of Science ®Google Scholar
• Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-I30
   PubMed Web of Science ®Google Scholar
• Mahan CE, Holdsworth MT, Welch SM, et al. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost 2011;106:405-15
   PubMed Web of Science ®Google Scholar
• Spyropoulos A, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
   PubMed Web of Science ®Google Scholar
• Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 2008;133:454S-545S
   PubMedGoogle Scholar
• Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 2008;133:141S-59S
   PubMedGoogle Scholar
• Rajgopal R, Bear M, Butcher MK, et al. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008;122:293-8
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 2008;133:160S-98S
   PubMed Web of Science ®Google Scholar
• Taro Pharmaceuticals U.S.A. I. (Warfarin sodium) Full prescribing information. 2011. http://www.drugs.com/pro/warfarin.html. Accessed February 6, 2012
   Google Scholar
• Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011;155:653
   PubMedGoogle Scholar
• Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011;32:2282-9
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Oake N, Fergusson DA, Forster AJ, et al. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007;176:1589-94
   PubMed Web of Science ®Google Scholar
• Rose AJ, Ozonoff A, Grant RW, et al. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009;2:591-7
   PubMed Web of Science ®Google Scholar
• Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005;165:1458-64
   PubMed Web of Science ®Google Scholar
• Amin A, Spyropoulos AC, Dobesh P, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis 2010;29:326-39
   PubMed Web of Science ®Google Scholar
• National Quality Forum. National voluntary consensus standards for prevention and care of venous thromboembolism: additional performance measures. Washington, DC: National Quality Forum, 2008. http://www.qualityforum.org/Publications/2008/10/National_Voluntary_Consensus_Standards_for_Prevention_and_Care_of_Venous_Thromboembolism__Additional_Performance_Measures.aspx. Accessed February 6, 2012
   Google Scholar
• Centers for Medicare and Medicaid Services. MA Payment guide for out of network payments. 2010. http://www.cms.gov/MedicareAdvtgSpecRateStats/Downloads/oon-payments.pdf. Accessed February 6, 2012
   Google Scholar
• The Joint Commission. National patient safety goals effective. 2012. http://www.jointcommission.org/assets/1/6/NPSG_Chapter_Jan2012_HAP.pdf. Accessed February 8, 2012
   Google Scholar
• Mahan C, Hussein MA, Amin AN, et al. Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis. Clin Appl Thromb Hemost 2012;18:45-58
   PubMedGoogle Scholar
• Centers for Medicare & Medicaid Services. Factsheet: improving quality of care during inpatient hospital stays. 2011. http://www.cms.gov/apps/media/press/factsheet.asp?Counter=4040&intNumPerPage=10&checkDate=&checkKey=&srchType=1&numDays=3500&srchOpt=0&srchData=&keywordType=All&chkNewsType=6&intPage=&showAll=&pYear=&year=&desc=false&cboOrder=date. Accessed February 9, 2012
   Google Scholar
• The Joint Commission. Hospital: 2011 National patient safety goals. 2011. http://www.jointcommission.org/hap_2011_npsgs/. Accessed February 6, 2012
   Google Scholar
• Centers for Medicare & Medicaid Services. CMS proposes to expand quality program for hospital inpatient services in FY 2009. 2007. http://www.cms.gov/apps/media/press/release.asp?Counter=3041. Accessed February 6, 2012
   Google Scholar
• Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006;96:274-84
   PubMed Web of Science ®Google Scholar
• Borris LC. Barriers to the optimal use of anticoagulants after orthopaedic surgery. Arch Orthop Trauma Surg 2009;129:1441-5
   PubMed Web of Science ®Google Scholar
• Tersteegen A, Schmidt S, Burkhardt N. Rivaroxaban - an oral, direct Factor Xa inhibitor - binds rapidly to Factor Xa. J Thromb Haemost 2007;5(2 Suppl):Abstract P-W-651
   Google Scholar
• Bayer Pharma AG. Xarelto® (rivaroxaban) summary of product characteristics. 2011. http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_Dec2011.pdf. Accessed February 6, 2012
   Google Scholar
• Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban - an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703-12
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Lassen MR, Kakkar AK, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effect on symptomatic venous thromboembolism and death, and bleeding. Haematologica 2009;94(2 Suppl):212, Abstract 0522
   Google Scholar
• The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Cohen AT, Spiro TE, Büller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011;31:407-16
   PubMed Web of Science ®Google Scholar
• Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. American College of Cardiology Congress 60th Annual Scientific Session. New Orleans, LA, April 2-5, 2011; Oral presentation. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_425442.pdf. Accessed February 8, 2012
   Google Scholar
• Bristol-Myers Squibb, Pfizer EEIG. Eliquis (apixaban) summary of product characteristics. 2011. http://www.eliquis.com/PDF/ELIQUIS%20®%20(apixaban)%20SmPC.pdf. Accessed February 6, 2012
   Google Scholar
• Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008;17:1937-45
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98
   PubMed Web of Science ®Google Scholar
• Huang J, Cao Y, Liao C, et al. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 2011;105:245-53
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:2167-77
   PubMed Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56
   PubMed Web of Science ®Google Scholar
• The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
   Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
   PubMed Web of Science ®Google Scholar
• Schulman S, Ericsson H, Goldhaber SZ, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011;9(2 Suppl):731, Abstract O-TH-033
   Google Scholar
• Schulman S, Baanstra D, Eriksson H, et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011;9(2 Suppl):22, Abstract O-MO-037
   Google Scholar
• Jensen CD, Steval A, Partington PF, et al. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br 2011;93:91-5
   PubMedGoogle Scholar
• Gent M, Kakkar AK, Eriksson BI, et al. A pooled analysis of surgical complications: results from the RECORD program. Annual Meeting of the American Academy of Orthopaedic Surgeons. New Orleans, LA, March 9-13, 2010; P096. http://www3.aaos.org/education/anmeet/anmt2010/poster/poster.cfm?Pevent=P096. Accessed February 8, 2012
   Google Scholar
• Gill SK, Theodorides A, Smith N, et al. Wound problems following hip arthroplasty before and after the introduction of a direct thrombin inhibitor for thromboprophylaxis. Hip Int 2011;21:678-83
   PubMedGoogle Scholar
• Stanek EJ, Agatep BC, Herrera V, et al. Assessment of initial US dabigatran utilization and short-term persistence. Circulation 2011;124:Abstract A16675
   Google Scholar
• Chambers S, Chadda S, Plumb JM. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. Int J Lab Hematol 2010;32:427-42
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Lees M, Wells PS, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010;104:760-70
   PubMed Web of Science ®Google Scholar
• Duran A, Sengupta N, Diamantopoulos A, et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective. Pharmacoeconomics 2012;30:87-101
   PubMed Web of Science ®Google Scholar
• Ryttberg L, Diamantopoulos A, Forster F, et al. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res 2011;11:601-15
   PubMed Web of Science ®Google Scholar
• Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009;31:194-212
   PubMed Web of Science ®Google Scholar
• McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009;27:829-46
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Sengupta N, Lees M. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Rev Pharmacoecon Outcomes Res 2011;11:299-306
   PubMed Web of Science ®Google Scholar
• Wolowacz SE. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Rev Pharmacoecon Outcomes Res 2011;11:9-25
   PubMed Web of Science ®Google Scholar
• Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) summary of product characteristics. 2011. http://www.medicines.org.uk/emc/medicine/20760. Accessed February 6, 2012
   Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9
   PubMed Web of Science ®Google Scholar
• Lu G, Luan P, Hollenbach S, et al. Reconstructed recombinant Factor Xa as an antidote to reverse anticoagulation by Factor Xa inhibitors. J Thromb Haemost 2009;7(2 Suppl):Abstract OC-TH-107
   Google Scholar
• Mahan CE, Spyropoulos AC. Peri-operative antithrombotic management and anticoagulant bridging. Can J Gen Intern Med 2011;6(1 Suppl):13-21
   Google Scholar
• Bratzler DW. Development of national performance measures on the prevention and treatment of venous thromboembolism. J Thromb Thrombolysis 2010;29:148-54
   PubMedGoogle Scholar
• Amin AN, Deitelzweig SB. Optimizing the prevention of venous thromboembolism: recent quality initiatives and strategies to drive improvement. Jt Comm J Qual Patient Saf 2009;35:558-64
   PubMedGoogle Scholar